47
Participants
Start Date
September 30, 2015
Primary Completion Date
February 28, 2018
Study Completion Date
March 23, 2020
Filanesib, pomalidomide and dexamethasone
Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
Hospital Doce de Octubre, Madrid
Hospital Morales Messeguer, Murcia
Clínica Universitaria de Navarra, Pamplona
Hospital Clinico Universitario Salamanca, Salamanca
Hospital General de Segovia, Segovia
Hospital Virgen del Rocío, Seville
Hospital Universitario Dr Peset, Valencia
Hospital Lozano Blesa, Zaragoza
Instoitut Català d'Oncologia, Badalona
Hospital Clinico Universitario, Barcelona
Collaborators (2)
Array BioPharma
INDUSTRY
Celgene Corporation
INDUSTRY
PETHEMA Foundation
OTHER